Akshay Vaishnaw - 05 Dec 2022 Form 4 Insider Report for ALNYLAM PHARMACEUTICALS, INC. (ALNY)

Role: President
Signature: By: /s/ Cynthia L Anderson, Attorney-in-Fact For: Akshay K. Vaishnaw
Issuer symbol: ALNY
Transactions as of: 05 Dec 2022
Net transactions value: +$449
Form type: 4
Filing time: 07 Dec 2022, 15:09:52 UTC
Previous filing: 05 Aug 2022
Next filing: 14 Feb 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ALNY	Common Stock	Options Exercise	$99,980	+1,124	+6.1%	$88.95	19,470	05 Dec 2022	Direct
transaction	ALNY	Common Stock	Options Exercise	$99,981	+1,587	+8.2%	$63.00	21,057	05 Dec 2022	Direct
transaction	ALNY	Common Stock	Options Exercise	$99,977	+2,368	+11%	$42.22^*	23,425	05 Dec 2022	Direct
transaction	ALNY	Common Stock	Tax liability	$299,489	-1,324	-5.7%	$226.20	22,101	05 Dec 2022	Direct
holding	ALNY	Common Stock						515	05 Dec 2022	by Managed Account	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ALNY	Stock Option (right to buy)	Options Exercise	$0	-2,368	-100%	$0.000000^*	0	05 Dec 2022	Common Stock	2,368	$42.22	Direct	F2
transaction	ALNY	Stock Option (right to buy)	Options Exercise	$0	-1,587	-4.9%	$0.000000	30,913	05 Dec 2022	Common Stock	1,587	$63.00	Direct	F2
transaction	ALNY	Stock Option (right to buy)	Options Exercise	$0	-1,124	-3.7%	$0.000000	28,876	05 Dec 2022	Common Stock	1,124	$88.95	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.
F2	The stock option vested as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter.